tazarotene has been researched along with Skin Neoplasms in 27 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of all-trans retinoic acid (ATRA), acitretin and tazarotene on apoptosis and Bax/Bcl-2 protein expressions of human melanoma A375 cells." | 7.73 | [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]. ( Lei, XB; Qiu, S; Ran, LW; Tan, SS; Wang, WJ; Zeng, WH, 2005) |
| "Tazarotene 0." | 6.71 | Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. ( Apisarnthanarax, N; Duvic, M; Kim, HW; Ni, X; Talpur, R; Ward, S, 2004) |
| "We report a case of an 83-year-old female with locally metastatic melanoma treated with imiquimod and tazarotene." | 3.74 | Treatment of locally metastatic melanoma: a novel approach. ( Fenske, NA; Glass, LF; Prakash, AV; Shistik, G, 2007) |
| "To investigate the effects of all-trans retinoic acid (ATRA), acitretin and tazarotene on apoptosis and Bax/Bcl-2 protein expressions of human melanoma A375 cells." | 3.73 | [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]. ( Lei, XB; Qiu, S; Ran, LW; Tan, SS; Wang, WJ; Zeng, WH, 2005) |
| "Tazarotene treatment was associated with increased TIG-3 protein and mRNA expression in basal cell carcinomas compared to baseline levels (p < or = 0." | 2.71 | Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. ( Duvic, M; Hazarika, P; Herne, K; Joseph, A; Ni, X; Schulz, C; Sui, D; Talpur, R; Ward, S, 2003) |
| "Tazarotene 0." | 2.71 | Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. ( Apisarnthanarax, N; Duvic, M; Kim, HW; Ni, X; Talpur, R; Ward, S, 2004) |
| "Tazarotene 0." | 2.71 | Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. ( Angeloni, C; Bianchi, L; Campione, E; Chimenti, S; Costanzo, A; Orlandi, A; Spagnoli, LG, 2004) |
| "Malignant melanoma is a form of skin cancer associated with significant mortality once it has spread beyond the skin." | 2.50 | Interventions for melanoma in situ, including lentigo maligna. ( Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T, 2014) |
| "Imiquimod cream has been used off-label as monotherapy in the treatment of LM and may be used in the neoadjuvant setting prior to staged excision as a strategy to reduce the size of the surgical margins required to confirm negative histologic margins." | 1.48 | Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision. ( Bowen, GM; Bowling, M; Donigan, JM; Goldgar, DE; Hadley, ML; Hyde, MA, 2018) |
| " When valproic acid is combined with tazarotene or isotretinoin, it does not change their photocarcinogenicity significantly." | 1.35 | Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice. ( Lerche, CM; Philipsen, PA; Sehested, M; Wulf, HC, 2008) |
| "Tazarotene was the most effective of the preparations studied, and its effect most likely was mediated by RARgamma activation." | 1.35 | Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. ( Epstein, EH; Fujimoto, MA; So, PL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Alomran, H | 1 |
| Kanitakis, J | 1 |
| Chambers, M | 1 |
| Swetter, SM | 1 |
| Baker, C | 1 |
| Saunders, E | 1 |
| Chapman, MS | 1 |
| Donigan, JM | 1 |
| Hyde, MA | 2 |
| Goldgar, DE | 1 |
| Hadley, ML | 2 |
| Bowling, M | 1 |
| Bowen, GM | 2 |
| Tseng, HW | 1 |
| Tseng, HH | 1 |
| Wu, CS | 2 |
| Tang, JY | 1 |
| Chiou, AS | 1 |
| Mackay-Wiggan, JM | 1 |
| Aszterbaum, M | 2 |
| Chanana, AM | 1 |
| Lee, W | 1 |
| Lindgren, JA | 1 |
| Raphael, MA | 1 |
| Thompson, BJ | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 5 |
| So, PL | 4 |
| Wang, GY | 2 |
| Wang, K | 1 |
| Chuang, M | 1 |
| Chiueh, VC | 1 |
| Kenny, PA | 1 |
| Chen, GS | 1 |
| Lin, PY | 1 |
| Pan, IH | 1 |
| Wang, ST | 1 |
| Lin, SH | 1 |
| Yu, HS | 1 |
| Lin, CC | 1 |
| Tzellos, T | 1 |
| Kyrgidis, A | 1 |
| Mocellin, S | 1 |
| Chan, AW | 1 |
| Pilati, P | 1 |
| Apalla, Z | 1 |
| Besner Morin, C | 1 |
| Roberge, D | 1 |
| Turchin, I | 1 |
| Petrogiannis-Haliotis, T | 1 |
| Popradi, G | 1 |
| Pehr, K | 1 |
| Lerche, CM | 1 |
| Philipsen, PA | 1 |
| Sehested, M | 1 |
| Wulf, HC | 1 |
| Resnik, KS | 1 |
| Kutzner, H | 1 |
| Modi, G | 1 |
| Jacobs, AA | 1 |
| Orengo, IF | 1 |
| McClung, A | 1 |
| Rosen, T | 1 |
| Brightman, L | 1 |
| Warycha, M | 1 |
| Anolik, R | 1 |
| Geronemus, R | 1 |
| Wang, L | 1 |
| Libove, E | 1 |
| Wang, J | 1 |
| Tristani-Firouzi, P | 1 |
| Goldgar, D | 1 |
| Bowman, PH | 1 |
| Davis, LS | 1 |
| Duvic, M | 2 |
| Ni, X | 2 |
| Talpur, R | 2 |
| Herne, K | 1 |
| Schulz, C | 1 |
| Sui, D | 1 |
| Ward, S | 2 |
| Joseph, A | 1 |
| Hazarika, P | 1 |
| Apisarnthanarax, N | 1 |
| Kim, HW | 1 |
| Orlandi, A | 2 |
| Bianchi, L | 2 |
| Costanzo, A | 2 |
| Campione, E | 2 |
| Giusto Spagnoli, L | 1 |
| Chimenti, S | 4 |
| Lee, K | 1 |
| Hebert, J | 1 |
| Walker, P | 1 |
| Lu, Y | 1 |
| Hwang, J | 1 |
| Kopelovich, L | 1 |
| Athar, M | 1 |
| Bickers, D | 1 |
| Angeloni, C | 1 |
| Spagnoli, LG | 1 |
| Peris, K | 2 |
| Ferrari, A | 1 |
| Fargnoli, MC | 2 |
| Piccolo, D | 1 |
| Bardazzi, F | 1 |
| Bianchi, F | 1 |
| Parente, G | 1 |
| Guareschi, E | 1 |
| Landi, C | 1 |
| Ran, LW | 1 |
| Tan, SS | 1 |
| Wang, WJ | 1 |
| Qiu, S | 1 |
| Lei, XB | 1 |
| Zeng, WH | 1 |
| Shistik, G | 1 |
| Prakash, AV | 1 |
| Fenske, NA | 1 |
| Glass, LF | 1 |
| Fujimoto, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome[NCT00489086] | Phase 2 | 36 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna[NCT00707174] | 90 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's target lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less." (NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | 2 |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
Negative histologic margins for the imiquimod plus tazarotene group compared to the imiquimod only group. (NCT00707174)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Imiquimod Only | 27 |
| Imiquimod and Tazarotene Combined | 29 |
3 reviews available for tazarotene and Skin Neoplasms
| Article | Year |
|---|---|
Adult-onset porokeratotic eccrine ostial and dermal duct nevus:dermatoscopic findings and treatment with tazarotene.
Topics: Administration, Topical; Adolescent; Adult; Aged; Dermatologic Agents; Eccrine Glands; Female; Human | 2020 |
Interventions for melanoma in situ, including lentigo maligna.
Topics: Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2014 |
Do lasers or topicals really work for nonmelanoma skin cancers?
Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2011 |
8 trials available for tazarotene and Skin Neoplasms
| Article | Year |
|---|---|
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
Topics: Adult; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cross-Over Studies; Dermatologic Agents; Do | 2014 |
Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans | 2016 |
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Bio | 2012 |
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.
Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Dermatologic Agents; Epider | 2003 |
Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
Topics: Administration, Topical; CD8 Antigens; Female; Gels; Humans; Immunohistochemistry; Leukocyte Common | 2004 |
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Basal Cell; Carcin | 2004 |
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X P | 2004 |
Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Dermatologic Agent | 2005 |
16 other studies available for tazarotene and Skin Neoplasms
| Article | Year |
|---|---|
Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up | 2021 |
Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Female; Follow-Up | 2018 |
Confluent and reticulate papillomatosis treated with minocycline and tazarotene.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Anti-Bacterial Agents; Dermatologic Agents; | 2013 |
PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Basal Cell; Cell Proliferation; Cell Transformatio | 2014 |
Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway.
Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Basal Cell; Caspa | 2014 |
Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice.
Topics: Administration, Cutaneous; Animals; Carcinogens; Dermatologic Agents; Dose-Response Relationship, Ra | 2008 |
Mimicry illuminating pitfalls in histopathologic diagnosis: nutritional deficiency-like dermatitis secondary to topical tazarotene and keratoacanthomatous pseudocarcinomatous hyperplasia in CD30+ lymphoproliferative disorder as illustrative.
Topics: Adolescent; Child; Dermatitis; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Hyperpl | 2009 |
Combination therapy with imiquimod, 5-fluorouracil, and tazarotene in the treatment of extensive radiation-induced Bowen's disease of the hands.
Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Bowen's Disease; Dermatologic Agents; Dose-Response | 2010 |
Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Basal Cell; Disease Models, Animal; Female; Hedgehog Prot | 2011 |
Confluent and reticulated papillomatosis: response to tazarotene.
Topics: Administration, Topical; Child; Dermatologic Agents; Female; Humans; Nicotinic Acids; Papilloma; Ski | 2003 |
Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation.
Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Carcinoma, Basal Cell; Female; Genetic Pr | 2004 |
A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ.
Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Derma | 2005 |
[Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance].
Topics: Acitretin; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Humans; Melanoma; Nicotinic | 2005 |
Treatment of locally metastatic melanoma: a novel approach.
Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy | 2007 |
Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Basal Cell; Hedgehog Proteins; Keratinocytes; Mice; Mic | 2008 |
Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Female; Gels; Huma | 1999 |